48 related articles for article (PubMed ID: 18083228)
1. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.
Pakjoo M; Ahmadi SE; Zahedi M; Jaafari N; Khademi R; Amini A; Safa M
Cell Commun Signal; 2024 Feb; 22(1):105. PubMed ID: 38331801
[TBL] [Abstract][Full Text] [Related]
2. [Update on biology of primary plasma cell leukemia].
Li Q; Sun CY; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):603-607. PubMed ID: 36709141
[No Abstract] [Full Text] [Related]
3. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
[TBL] [Abstract][Full Text] [Related]
5. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation.
Ozasa R; Hotta M; Yoshimura H; Nakanishi T; Tamaki T; Fujita S; Nakamichi N; Miyaji M; Ishii K; Ito T; Nomura S
Int Med Case Rep J; 2012; 5():39-43. PubMed ID: 23754921
[TBL] [Abstract][Full Text] [Related]
7. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
[TBL] [Abstract][Full Text] [Related]
8. How I treat plasma cell leukemia.
van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia.
Albarracin F; Fonseca R
Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
[TBL] [Abstract][Full Text] [Related]
10. Plasma cell leukaemia and other aggressive plasma cell malignancies.
Sher T; Miller KC; Deeb G; Lee K; Chanan-Khan A
Br J Haematol; 2010 Aug; 150(4):418-27. PubMed ID: 20701603
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell leukemia.
Gertz MA; Buadi FK
Haematologica; 2010 May; 95(5):705-7. PubMed ID: 20442443
[No Abstract] [Full Text] [Related]
12. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
Jimenez-Zepeda VH; Dominguez-Martinez VJ
Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
Chan SM; George T; Cherry AM; Medeiros BC
Cases J; 2009 Feb; 2(1):121. PubMed ID: 19192311
[TBL] [Abstract][Full Text] [Related]
14. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
16. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Grassinger J; Südhoff T; Andreesen R; Hennemann B
Ann Hematol; 2006 Feb; 85(2):132-3. PubMed ID: 16311736
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
18. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
